Krystal Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRYS research report →
About the company
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa.
- CEO
- Krish S. Krishnan
- IPO
- 2017
- Employees
- 275
- HQ
- Pittsburgh, PA, US
Price Chart
- Market Cap
- $11.06B
- P/E
- 48.40
- P/S
- 26.50
- P/B
- 8.60
- EV/EBITDA
- 52.65
- Div Yield
- 0.00%
- Gross Margin
- 92.79%
- Op Margin
- 42.85%
- Net Margin
- 53.92%
- ROE
- 19.25%
- ROIC
- 13.85%
- Revenue
- $389.13M · 33.94%
- Net Income
- $204.83M · 129.74%
- EPS
- $7.08 · 126.92%
- Op Income
- $161.29M
- FCF YoY
- 58.51%
- 52W High
- $382.54
- 52W Low
- $130.50
- 50D MA
- $311.01
- 200D MA
- $253.90
- Beta
- 0.53
- Avg Volume
- 313.10K
Get TickerSpark's AI analysis on KRYS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Thomas John Charles | other | 1,000 |
| Jun 25, 26 | Thomas John Charles | other | 1,000 |
| Jun 25, 26 | Thomas John Charles | sell | 1,000 |
| Jun 4, 26 | Krishnan Suma | sell | 320 |
| Jun 4, 26 | Krishnan Suma | sell | 593 |
| Jun 4, 26 | Krishnan Suma | sell | 247 |
| Jun 4, 26 | Krishnan Suma | sell | 400 |
| Jun 4, 26 | Krishnan Suma | sell | 480 |
| Jun 4, 26 | Krishnan Suma | sell | 1,348 |
| Jun 4, 26 | Krishnan Suma | sell | 12,729 |
Our KRYS coverage
Recent articles, reports, and earnings notes.
No research on KRYS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KRYS report →Similar companies
Peers in the same neighborhood.